Search Results - "Steven M Devine"

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes by Scott, Bart L, Pasquini, Marcelo C, Logan, Brent R, Wu, Juan, Devine, Steven M, Porter, David L, Maziarz, Richard T, Warlick, Erica D, Fernandez, Hugo F, Alyea, Edwin P, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L, Leifer, Eric, Le-Rademacher, Jennifer, Mendizabal, Adam M, Horowitz, Mary M, Deeg, H Joachim, Horwitz, Mitchell E

“…Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related…”
Get full text

Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide: Does Graft Source Matter? by Devine, Steven M

Get full text

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide by Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, Bolaños-Meade, Javier

“…Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors…”
Get full text

The Evolution of Hematopoietic Stem Cell Transplantation to Overcome Access Disparities: The Role of NMDP by Devine, Steven M

“…NMDP recognizes that despite advances in hematopoietic stem cell transplantation (HSCT) and other cell therapies, not all patients have equitable access to…”
Get full text

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD by Haverkos, Bradley M., Abbott, Diana, Hamadani, Mehdi, Armand, Philippe, Flowers, Mary E., Merryman, Reid, Kamdar, Manali, Kanate, Abraham Sebastian, Saad, Ayman, Mehta, Amitkumar, Ganguly, Siddhartha, Fenske, Timothy S., Hari, Parameswaran, Lowsky, Robert, Andritsos, Leslie, Jagasia, Madan, Bashey, Asad, Brown, Stacey, Bachanova, Veronika, Stephens, Deborah, Mineishi, Shin, Nakamura, Ryotaro, Chen, Yi-Bin, Blazar, Bruce R., Gutman, Jonathan, Devine, Steven M.

“…Given the limited treatment options for relapsed lymphoma post–allogeneic hematopoietic cell transplantation (post–allo-HCT) and the success of programmed…”
Get full text

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody by Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.

“…T-cell expression of programmed death receptor-1 (PD-1) down-regulates the immune response against malignancy by interacting with cognate ligands (eg, PD-L1)…”
Get full text

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts by Brunstein, Claudio G., Fuchs, Ephraim J., Carter, Shelly L., Karanes, Chatchada, Costa, Luciano J., Wu, Juan, Devine, Steven M., Wingard, John R., Aljitawi, Omar S., Cutler, Corey S., Jagasia, Madan H., Ballen, Karen K., Eapen, Mary, O'Donnell, Paul V.

“…The Blood and Marrow Transplant Clinical Trials Network conducted 2 parallel multicenter phase 2 trials for individuals with leukemia or lymphoma and no…”
Get full text

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial by ARMAND, Philippe, NAGLER, Arnon, FAY, Joseph W, RIZZIERI, David A, HOSING, Chitra M, BALL, Edward D, UBERTI, Joseph P, LAZARUS, Hillard M, MAPARA, Markus Y, GREGORY, Stephanie A, TIMMERMAN, John M, ANDORSKY, David, WELLER, Edie A, OR, Reuven, WALLER, Edmund K, ROTEM-YEHUDAR, Rinat, GORDON, Leo I, DEVINE, Steven M, AVIGAN, David E, CHEN, Yi-Bin, KAMINSKI, Mark S, KENT HOLLAND, H, WINTER, Jane N, MASON, James R

“…The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune…”
Get full text

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction by Devine, Steven M., Vij, Ravi, Rettig, Michael, Todt, Laura, McGlauchlen, Kiley, Fisher, Nicholas, Devine, Hollie, Link, Daniel C., Calandra, Gary, Bridger, Gary, Westervelt, Peter, DiPersio, John F.

“…Allografts from HLA-matched sibling donors were mobilized and collected without granulocyte colony-stimulating factor (G-CSF) using AMD3100, a direct…”
Get full text

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine by Blum, William, Garzon, Ramiro, Klisovic, Rebecca B, Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M, Chan, Kenneth K, Heerema, Nyla A, Bloomfield, Clara D, Grever, Michael R, Byrd, John C, Villalona-Calero, Miguel, Croce, Carlo M, Marcucci, Guido

“…A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who…”
Get full text

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Bredeson, Christopher, LeRademacher, Jennifer, Kato, Kazunobu, DiPersio, John F., Agura, Edward, Devine, Steven M., Appelbaum, Frederick R., Tomblyn, Marcie R., Laport, Ginna G., Zhu, Xiaochun, McCarthy, Philip L., Ho, Vincent T., Cooke, Kenneth R., Armstrong, Elizabeth, Smith, Angela, Rizzo, J. Douglas, Burkart, Jeanne M., Pasquini, Marcelo C.

“…We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation…”
Get full text

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? by Alousi, Amin M., Le-Rademacher, Jennifer, Saliba, Rima M., Appelbaum, Frederick R., Artz, Andrew, Benjamin, Jonathan, Devine, Steven M., Kan, Fangyu, Laughlin, Mary J., Lazarus, Hillard M., Liesveld, Jane, Perales, Miguel-Angel, Maziarz, Richard T., Sabloff, Mitchell, Waller, Edmund K., Eapen, Mary, Champlin, Richard E.

“…Older patients are increasingly undergoing allogeneic hematopoietic transplantation. A relevant question is whether outcomes can be improved with a younger…”
Get full text

Regulation of acute graft-versus-host disease by microRNA-155 by Ranganathan, Parvathi, Heaphy, Catherine E.A., Costinean, Stefan, Stauffer, Nicole, Na, Caroline, Hamadani, Mehdi, Santhanam, Ramasamy, Mao, Charlene, Taylor, Patricia A., Sandhu, Sukhinder, He, Gang, Shana'ah, Arwa, Nuovo, Gerard J., Lagana, Alessandro, Cascione, Luciano, Obad, Susanna, Broom, Oliver, Kauppinen, Sakari, Byrd, John C., Caligiuri, Michael, Perrotti, Danilo, Hadley, Gregg A., Marcucci, Guido, Devine, Steven M., Blazar, Bruce R., Croce, Carlo M., Garzon, Ramiro

“…Acute graft-versus-host disease (aGVHD) remains a major complication of allogeneic hematopoietic stem cell transplant (alloHSCT), underscoring the need to…”
Get full text

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia by BLUM, William, KLISOVIC, Rebecca B, PLASS, Christoph, DEVINE, Steven M, HEEREMA, Nyla A, MURGO, Anthony, CHAN, Kenneth K, GREVER, Michael R, BYRD, John C, MARCUCCI, Guido, HACKANSON, Bjoern, ZHONGFA LIU, SHUJUN LIU, DEVINE, Hollie, VUKOSAVLJEVIC, Tamara, HUYNH, Lenguyen, LOZANSKI, Gerard, KEFAUVER, Cheryl

“…To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with…”
Get full text

Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease by Chen, Yi-Bin, Perales, Miguel-Angel, Li, Shuli, Kempner, Maria, Reynolds, Carol, Brown, Jami, Efebera, Yvonne A., Devine, Steven M., El-Jawahri, Areej, McAfee, Steven L., Spitzer, Thomas R., Soiffer, Robert J., Ritz, Jerome, Cutler, Corey

“…Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains suboptimal. Preclinical data demonstrate increased CD30 expression on…”
Get full text

Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program by Farhadfar, Nosha, Newman, Jeni, Novakovich, Jennifer, Barten, Jacklyn, Ndifon, Eric T., Oakes, Jason, Cody, Meghann, Pham, Huy P., Auletta, Jeffery J., Miller, John P., Devine, Steven M., Stefanski, Heather E.

“…Background The Coronavirus Disease 2019 (COVID-19) pandemic in early 2020 has resulted in an unprecedented level of uncertainty and challenge for the stem cell…”
Get full text

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia by Blum, William, Schwind, Sebastian, Tarighat, Somayeh S., Geyer, Susan, Eisfeld, Ann-Kathrin, Whitman, Susan, Walker, Alison, Klisovic, Rebecca, Byrd, John C., Santhanam, Ramasamy, Wang, Hongyan, Curfman, John P., Devine, Steven M., Jacob, Samson, Garr, Celia, Kefauver, Cheryl, Perrotti, Danilo, Chan, Kenneth K., Bloomfield, Clara D., Caligiuri, Michael A., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido

“…We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical…”
Get full text

The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial by Armand, Philippe, Kim, Haesook T., Sainvil, Marie‐Michele, Lange, Paulina B., Giardino, Angela A., Bachanova, Veronika, Devine, Steven M., Waller, Edmund K., Jagirdar, Neera, Herrera, Alex F., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., McAfee, Steven L., Soiffer, Robert J., Chen, Yi‐Bin, Antin, Joseph H.

“…Summary Inhibition of the mechanistic target of rapamycin (mTOR) pathway has clinical activity in lymphoma. The mTOR inhibitor sirolimus has been used in the…”
Get full text

Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma by DEVINE, Steven M, FLOMENBERG, Neal, VESOLE, David H, LIESVELD, Jane, WEISDORF, Daniel, BADEL, Karin, CALANDRA, Gary, DIPERSIO, John F

“…Interactions between the chemokine receptor CXCR4 and its ligand stromal derived factor-1 regulate hematopoietic stem-cell trafficking. AMD3100 is a CXCR4…”
Get full text

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus -Host Disease by Snyder, Katiri J, Choe, Hannah K, Gao, Yandi, Sell, Natalie E, Braunreiter, Kara M, Zitzer, Nina C, Neidemire-Colley, Lotus, Kalyan, Sonu, Dorrance, Adrienne M, Keller, Andrea, Mihaylova, Maria M, Singh, Satishkumar, Sehgal, Lalit, Bollag, Gideon, Ma, Yan, Powell, Ben, Devine, Steven M, Ranganathan, Parvathi

“…Acute graft- -host disease (GVHD) is the leading cause of non-relapse mortality following allogeneic hematopoietic cell transplantation. The majority of…”
Get full text